Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

The closure of Sugen

Nature Biotechnology volume 21, page 969 (2003)Cite this article

To the editor:

I read with great interest the News story in the July issue (Nat. Biotechnol. 21, 722–723, 2003) on the closure of Sugen (S. San Francisco, CA, USA) in the wake of its takeover by Pfizer (New York, NY, USA). I was rather perplexed, however, to read the statement by Tony Hunter that Sugen was “a model of how to run a company.” Rather, the reverse is true, and this was the reason for the company's downfall.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Druker, B.J. et al. Nat. Med. 2, 561–566 (1996).

    Article  CAS  Google Scholar 

  2. Meydan, N. et al. Nature 379, 645–648 (1996).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, Hebrew University of Jerusalem, Jerusalem, 91904, Israel

    Alexander Levitzki

Authors
  1. Alexander Levitzki
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Levitzki, A. The closure of Sugen. Nat Biotechnol 21, 969 (2003). https://doi.org/10.1038/nbt0903-969a

Download citation

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0903-969a

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing